

Date and Time: 17 September 2014 1030 - 1630

Transfusion: Blood Transfusion

Guideline Development Group Meeting 11

Place: NCGC, 180 Great Portland Street, London, W1W 5QZ

Present: Mike Murphy (Chair) MM
Jennifer Hill (Guideline lead) JH
Smita Padhi (Senior Research Fellow) SP
Sophia Kemmis-Betty (Health Economist) SW
Sharangini Rajesh (Research Fellow) SR
Tamara Diaz (Project Manager) TD
Lindsay Dytham (Document Editor/Process Assistant) LD

Graham Donald (Patient Member) GD
Kenneth Halligan (Patient Member) KH
Mary Marsden (Transfusion Nurse) MMA
Helen New (Consultant Paediatrician) (HN)
Shubha Allard (Consultant Haematologist) (SA)

NICE Staff:	Katie Perryman-Ford (Guidelines commissioning manager)
Observers:	Katherine Ford (Junior Doctor)
Apologies:	Timothy Walsh (Anaesthetist/Intensivist) TW David Blackwell (Transfusion Practitioner) DB Karen Madgwick (Transfusion Lab Scientist) KM Susan Robinson (Consultant Haematologist) SR Dafydd Thomas (Consultant Anaesthetist) DT Robert Morris (Surgeon) RM

Notes

1. Introductions and apologies. MM welcomed the group to the 11th meeting of this GDG. Apologies were heard from TW, DB, KM, SR, DT and RM.
2. Declarations of Interests (DOIs). The Chair asked all GDG members to declare any relevant conflicts of interest since GDG 10. The following DOIs were noted from MM: he is a named author on some of the studies on patient information, relevant to reviews discussed at this GDG; he has no financial interest in this work. The following DOIs were noted from MMA: she uses octaplex, a drug which is used in some of the studies in the reviews at this GDG, and companies sometimes sponsor study days in her trust, but she has no personal pecuniary interest and has no preference for one PCC drug; MMA also declared that there is research into dabigatran in her trust currently but she is not involved in this research. The following DOIs were noted from SA: she is project lead for a national comparative audit looking at patient information and consent who are soon to publish a report, but she has no personal pecuniary interest. The following DOIs were noted from GD: he has been part of a team who has drafted patient referral leaflets, but no funds have been received.
None of these DOIs required further action for items on the day's agenda.
3. The draft NICE minutes of GDG 10. The Minutes of GDG 10 were agreed as a true and accurate account of the meeting.
4. Evidence review: Prothrombin complex concentrate. The clinical evidence was presented by SR. SKB presented the costs. The GDG discussed draft recommendations.
5. Evidence review: Patient information. The clinical evidence was presented by SP. SKB presented the costs. The GDG discussed draft recommendations.

Date, time and venue of the next meeting

1. GDG 12: 04 November 2014, 1030 – 1630 in the Boardroom, NCGC offices, 180 Great Portland Street, London, W1W 5QZ.